OB-101(01 Life)(OB-101(01 Life)) - 在研适应症：肥胖_专利_临床

概要

基本信息

药物类型

活菌制剂

别名

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

肥胖

非在研适应症-

原研机构

Shenzhen 01 Life Technology Co., Ltd.初创企业

在研机构

Shenzhen 01 Life Technology Co., Ltd.初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 OB-101(01 Life) 相关的临床结果

登录后查看更多信息

100 项与 OB-101(01 Life) 相关的转化医学

登录后查看更多信息

100 项与 OB-101(01 Life) 相关的专利（医药）

登录后查看更多信息

1

项与 OB-101(01 Life) 相关的文献（医药）

1999-05-01·Zhongguo yao li xue bao = Acta pharmacologica Sinica

Systemic anti-inflammation by synthetic interleukin-1 blockers.

Article

作者: Liu, S X ; Chiou, G C

AIMTo study the systemic anti-inflammatory actions of interleukin-1 (IL-1) blockers, OB-101 and OB-186.METHODSPrevention of palm swelling induced by carrageenin injection was used as an animal model of systemic anti-inflammation efficacy.RESULTSBoth OB-101 and OB-186 (10-30 mg.kg-1) were approximately 10-30-fold more potent than aspirin (300 mg.kg-1) to inhibit carrageenin-induced systemic inflammation. The LD50 of OB-101 and OB-186 were at least 20 g.kg-1 i.g., indicating that they were extremely safe agents with a therapeutic index (LD50/ED50) of at least 2000.CONCLUSIONThese IL-1 blockers are extremely safe systemically and are useable for the treatment of systemic inflammation such as rheumatoid arthritis.

100 项与 OB-101(01 Life) 相关的药物交易

登录后查看更多信息